---
document_datetime: 2023-09-21 20:53:13
document_pages: 46
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/atripla-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: atripla-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 22.611484
conversion_datetime: 2025-12-19 12:35:05.909944
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Atripla

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope Opinion/ Notification 1 issued on                                                                                                                                                                           | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0150              | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation 17/08/2021 product |                                             | SmPC and PL                      |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

Medicinal product no longer author

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IG/1412   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 28/07/2021    | n/a                               | authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|-----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0149   | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 09/06/2021    | SmPC and PL longer                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IG/1387   | B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 18/05/2021    | n/a                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0143/G | This was an application for a group of variations. - C.I.3.z (Type IB): Update of sections 4.4, 4.5 and 4.8 of the SmPC regarding the drug-drug interaction with didanosine and of section 4.8 of the SmPC regarding lactic acidosis, as agreed by the PRAC in the Viread procedure EMEA/H/C/PSUSA/00002892/201903, - C.I.3.z (Type IB): Update of section 4.5 of the SmPC to update the wording of the interaction between efavirenz and etonogestrel implants, as agreed by the PRAC in the Sustiva procedure EMEA/H/C/PSUSA/00001200/201804, - C.I.4 (Type II): Update of section 4.5 of the SmPC to state that co-administration of glecaprevir/pibrentasvir with Atripla is not recommended; the Package Leaflet is updated product | 11/06/2020 no | 17/06/2021 SmPC, Labelling and PL | SmPC new text Cases of lactic acidosis have been reported with tenofovir disoproxil alone or in combination with other antiretrovirals. Patients with predisposing factors such as severe hepatic impairment (CPT, Class C), or patients receiving concomitant medications known to induce lactic acidosis are at increased risk of experiencing severe lactic acidosis during tenofovir disoproxil treatment, including fatal outcomes. Co administration of Atripla and didanosine is not recommended. Increased systemic exposure to didanosine may increase didanosine related adverse reactions. Rarely, pancreatitis and lactic acidosis, sometimes fatal, have been reported. Co administration of tenofovir disoproxil and didanosine at a dose of 400 mg daily has been associated with a significant decrease in CD4 cell count, possibly due to an intracellular interaction increasing phosphorylated |

<!-- image -->

<div style=\"page-break-after: always\"></div>

IG/1243

<!-- image -->

(i.e. active) didanosine. A decreased dosage of 250 mg didanosine co administered with tenofovir disoproxil therapy has been associated with reports of high rates of virological failure within several tested combinations for the treatment of HIV 1 infection.

Concomitant administration of glecaprevir/pibrentasvir with efavirenz, a component of Atripla, may significantly decrease plasma concentrations of glecaprevir and pibrentasvir, leading to reduced therapeutic effect. Coadministration of glecaprevir/pibrentasvir with Atripla is not recommended.

For more information, please refer to the Summary of Product Characteristics.

accordingly. In addition, the drugs boceprevir, nelfinavir and simeprevir, which have been withdrawn from the European Market, were removed from the PI. The MAH also took the opportunity to make editorial corrections and update the PI in line with the Annex to the European Commission guideline on `Excipients in the labelling and package leaflet of medicinal products for human use' (EMA/CHMP/302620/2017 Rev.1) regarding sodium content. Furthermore, the PI is brought in line with the latest QRD template version 10.1. C.I.3.a - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Implementation of wording agreed by the competent authority C.I.3.a - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Implementation of wording agreed by the competent authority C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or 25/05/2020 n/a Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                                                                                                                   |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/1247   | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                    | 08/05/2020 | n/a        |                        | authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IG/1236   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                        | 04/05/2020 | n/a        | longer                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IAIN/0144 | C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority                                                                                                                                                                                                                                                           | 17/04/2020 | n/a no     |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| T/0142    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                 | 31/01/2020 | 17/02/2020 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| WS/1509   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Submission of updated RMPs version 18.0 for Atripla and version 16.0 for Truvada, in order to: 1) implement Revision 2 of the EU-RMP template and amend the safety concerns accordingly, 2) remove the additional risk minimisation measures for tenofovir disoproxil fumarate in the form of product | 14/03/2019 | 13/09/2019 | Annex II               | The Annex IID 'Conditions or restrictions with regard to the safe and effective use of the medicinal product' of Atripla and Truvada was amended to remove the HIV renal educational brochure (including the creatinine clearance slide ruler) for adults, in line with a previous CHMP decision for tenofovir disoproxil-containing products. In addition, the Annex IIIB (Package Leaflet) of Truvada was revised to amend the recommendation pertaining to pregnancy in line with the SmPC recommendation, to remove the following statement from Section 2 - What you need to know before |

<div style=\"page-break-after: always\"></div>

you take Truvada: 'If you are a woman who could get pregnant during treatment with Truvada, you must use an effective method of contraception to avoid becoming pregnant.'

education materials regarding renal toxicity and bone events, with the resulting amendment of Annex II of the product information, 3) add clinical data from study GS-US-104-0352 (A Phase III, Randomized, Open-Label Study Comparing the Safety and Efficacy of Switching Stavudine or Zidovudine to Tenofovir Disoproxil Fumarate Versus Continuing Stavudine or Zidovudine in Virologically Suppressed HIV-Infected Children Taking Highly Active Antiretroviral Therapy), 4) revise the due dates for two category 3 studies for Truvada, GS-US-276-0103 (A Prospective, Observational Study of Individuals Who Seroconvert While Taking Truvada for Pre Exposure Prophylaxis (PrEP)) and GS-EU-276-4027 (A Cross-Sectional Post Authorization Safety Study to Assess Healthcare Provider's Level of Awareness of Risk Minimisation Materials for Truvada for Pre Exposure Prophylaxis in the European Union), 5) change the Marketing Authorisation Holder's (MAH) name from Gilead Sciences International Ltd. to Gilead Sciences Ireland UC., 6) update the milestones for the Truvada study GS-US-276-0104 (Seroconversions, Resistance, Adverse Events and Drug Adherence among Subjects taking Truvada for PrEP: A Nested Case Control study) in the Truvada EU-RMP and 7) correct a discrepancy in Annex IIIB of the Truvada PI regarding the recommendation pertaining to pregnancy, by aligning the PL wording with that of the SmPC. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                    | authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                                                                                                                                                                                                                                                                                                               |            |            | authorised                        |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------------------|
| PSUSA/1201/ 201807 | Periodic Safety Update EU Single assessment - efavirenz / emtricitabine / tenofovir                                                                                                                                                                                                                                                                                                                                                                                                                                               | 14/02/2019 | n/a        | PRAC Recommendation - maintenance |
| IA/0141            | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                               | 11/02/2019 | n/a        | longer                            |
| N/0140             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                  | 05/02/2019 | 13/09/2019 | PL                                |
| IA/0139            | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 14/12/2018 | n/a no     |                                   |
| WS/1466/G          | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation product | 29/11/2018 | n/a        |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                             |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/1447 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.d.1.z - Stability of AS - Change in the re-test period/storage period or storage conditions - Other variation                                                                                                                                                          | 04/10/2018 | n/a        | longer                 | authorised                                                                                                                                                                                                                                                                                                                                                                                                                                |
| IG/0985 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                           | 28/09/2018 | 13/09/2019 | SmPC                   |                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IG/0974 | B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                                                                                                                                      | 07/09/2018 | n/a no     |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| N/0131  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                         | 25/07/2018 | 22/11/2018 | PL                     |                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| II/0129 | Update of sections 4.4 and 4.5 of the Atripla SmPC in order to add a warning that co administration of Atripla and sofosbuvir/velpatasvir/voxilaprevir is not recommended, and reflect the corresponding drug- drug interaction data based on the final results from study GS-US-342-1167, listed as category 3 study in the RMP: a phase I study to evaluate the pharmacokinetic drug-drug interactions between product | 17/05/2018 | 22/11/2018 | SmPC, Labelling and PL | The Marketing Authorisation Holder has submitted the results of Study GS-US-342-1167, a phase I pharmacokinetic drug-drug interaction study. The results suggest that co administration of Atripla and sofosbuvir/velpatasvir or sofosbuvir/velpatasvir/voxilaprevir should not be recommended since plasma concentrations of velpatasvir and voxilaprevir are expected to decrease following co administration with efavirenz leading to |

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | new quality, preclinical, clinical or pharmacovigilance data C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority                                                                                                                                                                                                                                                                           |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0128   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient 12/02/2018                                                                                                                                                                                                                                                                          |
| IG/0845   | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS 18/12/2017 no                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0125/G | This was an application for a group of variations. B.I.a.2.b (Type II) - To add route 8 as alternative synthesis route for efavirenz active substance B.I.a.1.f (Type IA) - To add Siegfried Evionnaz SA, Route du Simplon 1, 36, 1902 Evionnaz, Switzerland as stability QC testing site for efavirenz active substance B.I.a.1.f (Type IA) - To add Solvias AG, Romerpark 2, 4303 Kaiseraugst, Switzerland as QC testing site for efavirenz active substance B.I.a.3.b (Type IA) - To reduce the batch size 26/10/2017 product |

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IG/0799   | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 14/07/2017   | n/a                              | authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0122/G | This was an application for a group of variations. B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 09/06/2017   | n/a                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| WS/1133/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Updates of sections 4.4 and 4.5 of the SmPC for the tenofovir disoproxil fumarate (TDF)-containing products (Viread, Truvada, Atripla, Stribild) which includes the results from Study GS-US-342-1167 and Study GS-US-342-1326. The Package Leaflets and Risk Management Plans for Viread (v. 22), Truvada (v.14), Atripla (v.16) and Stribild (v.11.1) have been updated accordingly. Update of section 4.5 for the tenofovir alafenamide (TAF)-containing products (Genvoya, Descovy, Odefsey) and for Eviplera, which include the results from Study GS-US-342-1167. The Risk Management product | 21/04/2017   | 23/03/2018 SmPC and PL no longer | The Marketing Authorisation Holder has submitted the results from Study GS-US-342-1167 and Study GS-US- 342-1326 to update the Product Information for tenofovir disoproxil fumarate (TDF)-containing products (Viread, Truvada, Atripla, Eviplera and Stribild) and tenofovir alafenamide (TAF)-containing products (Genvoya, Descovy, Odefsey). Study GS-US-342-1167 is a Phase I Study to Evaluate the Pharmacokinetic Drug-Drug Interactions between Sofosbuvir/GS-5815 Fixed Dose Combination (FDC) Tablets and Antiretrovirals Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF; Atripla), Emtricitabine/Riplivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF; Complera), Dolutegravir (DTG; Tivicay) o Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate (EVG/COBI/FTC/TAF) in Healthy Subjects. The recommendation stemming from this study is that no dose |

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

adjustment of sofosbuvir/velpatasvir with Eviplera orGenvoya is warranted upon co-administration, and that Atripla should not be co-administered with sofosbuvir/velpatasvir.

Study GS-US-342-1326, a Phase I Study to Evaluate the Pharmacokinetic Drug-Drug Interaction Potential between Sofosbuvir/GS-5816 (SOF/GS-5816) Fixed-Dose Combination (FDC) Tablet and HIV Antiretroviral Regimens Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (EVG/COBI/FTC/TDF), Ritonavir-boosted Darunavir (DRV/r) plus Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF), Ritonavir-boosted Atazanavir (ATV/r) plus FTC/TDF, Ritonavir/boosted Lopinavir (LPV/r) plus FTC/TDF or Raltegravir plus FTC/TDF. Results showed that no dose adjustment is recommended.  The increased exposure of tenofovir could potentiate adverse reactions associated with tenofovir disoproxil fumarate, including renal disorders.  Renal function should be closely monitored.

Plan for Eviplera (v.13) has been updated accordingly. Administrative update of section 4.8 of the SmPC for Viread, Atripla, Eviplera and Stribild. Study GS-US-342-1167 is  a Phase I Study to Evaluate the Pharmacokinetic Drug-Drug Interactions between Sofosbuvir/GS-5815 Fixed Dose Combination (FDC) Tablets and Antiretrovirals Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF; Atripla), Emtricitabine/Riplivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF; Complera), Dolutegravir (DTG; Tivicay) o Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate (EVG/COBI/FTC/TAF) in Healthy Subjects. Study GS-US-342-1326, a Phase I Study to Evaluate the Pharmacokinetic Drug-Drug Interaction Potential between Sofosbuvir/GS-5816 (SOF/GS-5816) FixedDose Combination (FDC) Tablet and HIV Antiretroviral Regimens Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (EVG/COBI/FTC/TDF), Ritonavirboosted Darunavir (DRV/r) plus Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF), Ritonavir-boosted Atazanavir (ATV/r) plus FTC/TDF, Ritonavir/boosted Lopinavir (LPV/r) plus FTC/TDF or Raltegravir plus FTC/TDF. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                 |                    |            | authorised             |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|------------|------------------------|
| IG/0745 | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place             | 28/11/2016         | n/a        |                        |
| IG/0725 | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient           | 21/10/2016         | n/a no     | longer                 |
| IG/0726 | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient           | 19/09/2016 product | n/a        |                        |
| WS/0963 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation Medicinal | 15/09/2016         | 16/12/2016 | SmPC, Labelling and PL |
| IA/0116 | A.4 - Administrative change - Change in the name                                                                                                                                                                                                       | 03/08/2016         | n/a        |                        |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                                                                                                             |                       |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| WS/0860/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing                                                                                                                                                                                                        | 26/05/2016 n/a longer |
| IA/0115/G | authorisation, including the RMP - Other variation This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient product | 25/05/2016 n/a no     |
| IG/0671   | B.I.d.1.c - Stability of AS - Change in the re-test                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 14/04/2016 n/a        |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | period/storage period or storage conditions - Change to an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0829 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                             | 01/04/2016 | 16/12/2016 SmPC, Annex II and PL | authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| WS/0792 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 4.4 of the SmPC in order to revise the HIV class label wording on mitochondrial dysfunction following the review of existing data on mitochondrial toxicity including the Mitochondrial Toxicity in Children (MITOC) Study. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data Medicinal product | 01/04/2016 | 16/12/2016 SmPC and PL no longer | Nucleos(t)ide analogues may impact mitochondrial function to a variable degree, which is most pronounced with stavudine, didanosine and zidovudine. There have been reports of mitochondrial dysfunction in HIV negative infants exposed in utero and/or postnatally to nucleoside analogues; these have predominantly concerned treatment with regimens containing zidovudine. The main adverse reactions reported are haematological disorders (anaemia, neutropenia) and metabolic disorders (hyperlactatemia, hyperlipasemia). These events have often been transitory. Late onset neurological disorders have been reported rarely (hypertonia, convulsion, abnormal behaviour). Whether such neurological disorders are transient or permanent is currently unknown. These findings should be considered for any child exposed in utero to nucleos(t)ide analogues, that present with severe clinical findings of unknown etiology, particularly neurologic findings. These findings do not affect current national recommendations to use antiretroviral therapy in pregnant women to prevent vertical transmission of HIV. |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| PSUSA/1201/ 201507   | Periodic Safety Update EU Single assessment - efavirenz / emtricitabine / tenofovir                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 11/02/2016   | n/a                    |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------------------|
| IG/0651              | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 28/01/2016   | n/a authorised         |
| WS/0884              | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                           | 28/01/2016   | 16/12/2016 SmPC and PL |
| IG/0624              | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 11/01/2016   | n/a SmPC no longer     |
| WS/0731              | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Submission of the final clinical study report for Viread study GS-US-104-0423 'A Phase 4 Cross- Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects' in fulfilment of a post- authorisation measure (PAM) for Viread, Truvada, Eviplera, Stribild and Atripla (category 3 additional pharmacovigilance activity for Viread, Truvada, Eviplera and Stribild, and category 4 for Atripla). An updated RMP (version 18.0 for Viread, 9.0 for Truvada, 13.0 for Atripla, 9.0 for Eviplera and 6.0 for product | 17/12/2015   | 16/12/2016             |

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IG/0572   | new quality, preclinical, clinical or pharmacovigilance data C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                         | 09/06/2015   | 14/12/2015                            | changes in drug exposures that are not considered clinically relevant. No drug interaction data are available for concomitant administration of emtricitabine and simeprevir. However, based on the differential ADME profiles and the lack of in vitro interactions with CYPs and transporters, the theoretical risk of a drug-drug interaction between the emtricitabine component of Atripla and simeprevir is considered highly unlikely. Due to the observed interaction with efavirenz co-administration of simeprevir (Olysio) with Atripla is not recommended. SmPC and PL longer authorised   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0553   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                        | 07/05/2015   | n/a no                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| IG/0521   | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release product                                                                                                                                                                                                                  | 26/02/2015   | 14/12/2015 Annex II and PL 14/12/2015 | The MAH has provided literature references to support the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| WS/0650   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 5.1 of the SmPC to include reference to the tenofovir resistance-associated substitution K70E. In addition, the product information has been updated to reflect the right Medicinal | 18/12/2014   | SmPC, Labelling and PL                | proposal to include information regarding the K70E mutation resulting in reduced tenofovir disoproxil fumarate (TDF) susceptibility in section 5.1 of the SmPC of Atripla, Truvada and Viread as follows: \"In addition, a K70E substitution in HIV-1 RT has been selected by tenofovir and results in low-level reduced susceptibility to abacavir,                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | expression of pack sizes. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                       |            |        | emtricitabine, lamivudine and tenofovir.\" authorised   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|--------|--------------------------------------------------------|
| IA/0098 | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                  | 20/11/2014 | n/a    |                                                        |
| II/0088 | Addition of an alternative manufacturing process for the synthesis of the active substance B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product | 23/10/2014 | n/a no | longer                                                 |
| WS/0599 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority product               | 25/09/2014 | n/a    |                                                        |
| IG/0479 | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure Medicinal                                                                                                                                                                     | 17/09/2014 | n/a    |                                                        |

<div style=\"page-break-after: always\"></div>

| IA/0094/G   | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                        | 08/08/2014   | n/a                 | authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0095   | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 07/08/2014   | n/a                 | longer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| WS/0586     | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. WSA for Atripla, Truvada, Stribild, Viread and Eviplera to update sections 4.4 and 4.8 of the SmPC for all tenofovir disoproxil fumarate (TDF)-containing products to revise the renal monitoring recommendations and to implement additional renal safety information. The Package Leaflet was updated accordingly and the key messages for the annex II for Viread and Atripla were updated to reflect this information as appropriate. The MAH submitted this variation in fulfilment of a post-autorisation measure for Viread on the reversibility of TDF associated renal tubulopathy. product | 24/07/2014   | 22/01/2015 SmPC, no | In fulfilment of a CHMP request for Viread pertaining to the reversibility of TDF associated renal tubulopathy, the MAH has submitted a worksharing variation to implementing renal safety information in the SmPC of all the TDF- containing products. The main messages on renal safety are the following: to differentiate the monitoring depending on the presence of renal risk factors (reinforced monitoring) or not (standard monitoring); to consider interruption of treatment with tenofovir disoproxil fumarate in case of progressive decline of renal function when no other cause has been identified; to reflect the impact of the NSAIDs and boosted PIs in renal function and to inform prescribers that in some patients, renal function did not completely resolve despite tenofovir disoproxil fumarate discontinuation. |

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0575   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 4.4 of the SmPC in order to update the safety information on the risk of renal injury in patients with risk factors for renal dysfunction after co-administration of non-steroidal anti-inflamatory drugs (NSAIDs) with tenofovir, following a cumulative review requested by PRAC. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to bring the PI of Truvada in line with the latest QRD template version 9. 24/07/2014 22/01/2015 SmPC, Labelling and PL Available data from spontaneous cases and the literature suggest that the co-administration of non-steroidal anti- inflammatory drugs (NSAIDs) with tenofovir may expose patients to a higher risk of renal injury, especially if they present additional risk factors for renal impairment. In this worksharing procedure the MAH has updated section 4.4 of the SmPC and section 2 of the PL for Viread, Truvada, Atripla, Eviplera and Stribild to include a specific warning in patients with risk factors for renal dysfunction, following a cumulative review requested by PRAC. no longer authorised |
| IAIN/0092 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation Introduction of an agreed wording (section 4.6 of the SmPC) regarding the number of pregnancies and Neutral Tube Defects (NTD) for efavirenz after the PRAC assessment and following implementation of the same wording in the SmPC for Sustiva. C.I.3.a - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure 16/07/2014 22/01/2015 SmPC Medicinal product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Implementation of wording agreed by the competent authority                                                                                                                                                                                                                                               |            |               |                        | authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0448   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                            | 02/07/2014 | n/a           |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| II/0084   | Update of section 4.5 of the SmPC concerning information on false positive results in screening tests for cannabinoid metabolites in line with the changes for the efavirenz component adopted by the CHMP on 23 January 2014 (Sustiva/Stocrin EMEA/H/C/XXXX/WS/434). C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 22/05/2014 | 22/01/2015 no | SmPC longer            | A literature review indicated that efavirenz may interfere with the results of a number of commercially available tests used for routine screening of cannabinoid use, and not just one test as had been previously included in the SmPC. Section 4.5 of the SmPC was updated with a more general statement (mention of specific assays was removed) and with a recommendation for confirmation of positive screening tests by a more specific method, such as GC/MS. This update in line with the changes for the efavirenz (EFV) component, which were previously approved by the CHMP for Sustiva/Stocrin (efavirenz) |
| IAIN/0085 | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location product                                                                                                                                                                                                                 | 31/03/2014 | n/a           |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| WS/0530   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 4.4 'Special warnings and Medicinal                                                                                                                                                                                     | 20/03/2014 | 22/01/2015    | SmPC, Labelling and PL | During recent years conclusive evidence has been collected which shows that the risk for HIV patients, who are well treated, to sexually transmit HIV to their partner is exceedingly low. A position statement on the use of antiretroviral therapy to reduce HIV transmission was                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|         | precautions for use' of the SmPC for Atripla, Emtriva, Eviplera, Stribild, Truvada, Viread and Vitekta to revise the wording regarding the risk of sexual transmission of HIV infection following CHMP request adopted in December 2013. The PL has been updated accordingly. Furthermore, the MAH took the opportunity of this worksharing to update the PL with the details of the local representatives for Croatia and to introduce the Croatian language annexes for Emtriva and to update the bottle label to include the EDQM short standard term for the pharmaceutical form for Stribild. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation   | no                    | longer      | published by the British HIV Association (BHIVA) in January 2013. As a consequence, the recommendations for post- exposure prophylaxis have also been changed in recently updated HIV treatment guidelines. For example, the 2013 BHIVA guideline does not generally recommend post- exposure prophylaxis (PEP) after exposure from a patient with well treated HIV. Based on these data, the wording on the risk of transmission for HIV products was revised to reflect the current scientific knowledge. While effective suppression with antiretroviral therapy has been proven to substantially reduce the risk of sexual transmission, a residual risk cannot be excluded. Precautions to prevent transmission should be taken in accordance with national guidelines. authorised   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0081 | Update of section 4.6 of the SmPC with information on the excretion of efavirenz (EFV) into human breast milk in line with the changes approved for the efavirenz single product. Furthermore, the MAH took the opportunity of this variations to include minor changes for consistency. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data product                                                                                                                                                                                                                                                                                  | 20/02/2014 22/01/2015 | SmPC and PL | A published study analysing the levels of efavirenz in plasma and breast milk of 13 breast-feeding mothers and in the plasma of their non-antiretroviral-treated infants. Results from this study demonstrated that efavirenz passes easily into human milk, with a strong correlation between the levels in maternal plasma and breast milk, as well as between the levels in milk and plasma levels in breast- feeding infants. There is insufficient information on the effects of efavirenz in newborns/infants. Importantly, HIV- infected mothers should not breast-feed under any circumstances to avoid HIV transmission to the infant.                                                                                                                                           |
| II/0080 | Update of section 4.5 of the SmPC on interactions with artemether/lumefantrine in line with the changes approved for the efavirenz single product. The PL was updated accordingly. Moreover the MAH Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 20/02/2014 22/01/2015 | SmPC and PL | In a drug-drug interaction study in healthy volunteers coadministration of efavirenz with the antimalarial artemisinin-based combination therapy artemether/lumefantrine resulted in reduced exposure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | took the opportunity of this variation to implement minor linguistic amendments in the Swedish PL. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0082/G | This was an application for a group of variations. B.I.b.1.h - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition or replacement (excl. Biol. or immunol. substance) of a specification parameter as a result of a safety or quality issue B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place 03/02/2014 n/a to to reflect the most recent discussions on the potential safety concerns; to add the required study ACTG5224 in the pharmacovigilance plan; to include the results of several completed studies; to include product no longer |
| II/0077   | The MAH has submitted an updated RMP version 12 23/01/2014 n/a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | RMP to the RMPs of other products containing the components of Atripla. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                                                                                                                                                                                                                                          |            |               | longer      | authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0075 | Update of section 4.5 of the SmPC with information on the drug-drug interaction with the HCV protease inhibitors boceprevir and telaprevir and with additional information on the interaction with rifabutin. The PL is updated accordingly. In addition, the PI is being brought in line with the latest QRD template version 9. The PL further is updated to include minor amendments for clarity. The MAH also took this opportunity to implement a minor linguistic correction in the DE annexes. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data product | 23/01/2014 | 22/01/2015 no | SmPC and PL | This procedure aimed to update section 4.5 of the SmPC to include information on the interaction of efavirenz with the HCV NS3 protease inhibitors telaprevir and boceprevir and to complement information on the interaction with rifabutin. The drug-drug interaction information on concomitant use of efavirenz with either boceprevir or telaprevir was updated consistently with their respective SmPCs. Additionally, the SmPC was updated to inform prescribers that the recommended dose adjustments for rifabutin when coadministered with efavirenz have not been clinically evaluated. These updates for atripla (fixed-dose combination of efavirenz , emtricitabine and tenofovir disoproxil fumarate) are in line with the approved SmPC for efavirenz (Sustiva/Stocrin). |
| IB/0079 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 21/01/2014 | 22/01/2015    | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| WS/0398 | This was an application for a variation following a worksharing procedure according to Article 20 of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 18/12/2013 | n/a           |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | Commission Regulation (EC) No 1234/2008. To introduce a minor change to the manufacturing process of tenofovir disoproxil fumarate (TDF) active substance. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                           |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0378 | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or 29/11/2013                                                                                             |
| IG/0368 | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS 07/11/2013 no                                                                                                                                                                                    |
| WS/0422 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. This is a type IB variation application following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008, to 24/10/2013 product |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |                                            | variation   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|--------------------------------------------|-------------|
| IAIN/0074 | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 02/10/2013 | n/a authorised                             |             |
| WS/0391   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.4 and 4.8 of the SmPC in order to update the safety information regarding autoimmune disorders in relation to Immune Reactivation Syndrome, following a class labelling for antiretrovirals as requested by the CHMP. The Package Leaflet was updated accordingly. In addition, the WSA took the opportunity to update the list of local representatives in the Package Leaflet. Furthermore, Annex II is being brought in line with the latest QRD template version and minor editorial changes are implemented in the SmPC. C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH Medicinal product | 30/05/2013 | 13/06/2013 SmPC, Annex II and PL no longer |             |
| IG/0288   | A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 05/04/2013 | n/a                                        |             |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |               |                    | authorised                                                                                                                                                                                                                                                                                                                                                                                    |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0294 | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 03/04/2013 | n/a           |                    |                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0067 | Update of sections 4.2, 4.4, 4.5 and 5.2 of the SmPC on mechanism of interactions and in particular on interactions with darunavir, bupropion, rifampicin, atovaquone/proguanil and acenocoumarol and with respect to metabolic enzymes . Section 4.8 is also updated to add hypertriglyceridaemia, hypercholesterolaemia, elevated aspartate aminotransferase, elevated alanine aminotransferase and elevated gamma-glutamyltransferase. The Package Leaflet is updated accordingly. In addition the MAH took the opportunity of this variation to correct minor linguistic error to the French version of the PL. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data product | 13/12/2012 | 13/06/2013 no | SmPC and PL longer |                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0066 | The MAH proposed the update of sections 4.2 and 5.2 of the SmPC on tenofovir exposure when taken on an empty stomach and the update of section 5.1 of the SmPC to include data from the extension phase of Study GS-01-934. This submission addresses CHMP request during the Renewal (EMEA/H/C/000797/R/0062). Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 13/12/2012 | 13/06/2013    | SmPC and Annex II  | Sections 4.2 and 5.2 of the SmPC were updated on level of tenofovir exposure when taken on an empty stomach. It is anticipated that tenofovir exposure (AUC) will be approximately 30% lower following administration of Atripla on an empty stomach as compared to the individual component tenofovir disoproxil fumarate when taken with food. Compared to fasted administration, dosing of |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         |                                                                                                                                                                                                                                                                                                                                                                         |               |                | and PL     |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|----------------|------------|
| IG/0203 | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                        | 03/08/2012    | n/a            | authorised |
| WS/0245 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Addition of a new manufacturing and quality control testing site for the active substance. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation           | 21/06/2012    | 21/06/2012     | longer     |
| WS/0244 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Minor change in the manufacturing process of the active substance tenofovir disoproxil fumarate. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS product | 24/05/2012 no | 24/05/2012 n/a |            |
| IA/0063 | C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system Medicinal                                                                                                                                                                        | 13/04/2012    |                |            |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IB/0057   | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                              | 19/01/2012    | n/a                    | authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0058   | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                                                                                                                                          | 04/01/2012    | n/a                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IB/0059   | B.II.b.3.a - Change in the manufacturing process of the finished product - Minor change in the manufacturing process of an immediate release solid oral dosage form or oral solutions                                                                                                                                                                                                                                                                         | 16/12/2011    | n/a                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| II/0050   | Update of section 4.6 of the Summary of Product Characteristics (SmPC) on efavirenz to be in line with Sustiva (efavirenz). In addition, the MAH took the opportunity to make a minor correction on section 4.4 of the SmPC and to make linguistic corrections to the Polish version C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data Medicinal product | 20/10/2011 no | 22/11/2011 SmPC longer | The Antiretroviral Pregnancy Registry (APR) has received, as of July 2010 prospective reports of 718 pregnancies with first-trimester exposure to efavirenz-containing regimens, resulting in 604 live births. One child was reported to have a neural tube defect, and the frequency and pattern of other birth defects were similar to those seen in children exposed to non efavirenz containing regimens, as well as those in HIV negative controls. The incidence of neural tube defects in the general population ranges from 0.5 1 case per 1,000 live births. In retrospective reports, there have been six cases of findings consistent with neural tube defects including meningomyelocele, all in mothers exposed to efavirenz containing regimens in the first trimester. A causal relationship of these events to the use of efavirenz has not been established and the total number of pregnant women exposed to efavirenz-containing regimens is unknown. As neural tube defects occur within the first 4 |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           |                                                                                                                                                                                                                                                                                                                                         |            | longer   |                              |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----------|------------------------------|
| IA/0051/G | This was an application for a group of variations. C.I.9.d - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the safety database C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of product | 26/10/2011 | n/a no   | the pharmacovigilance system |
| IA/0052/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place Medicinal                                          | 20/10/2011 | n/a      |                              |

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.II.b.3.a - Change in the manufacturing process of the finished product - Minor change in the manufacturing process of an immediate release solid oral dosage form or oral solutions                                                                                                                                                                                                                                                                                                                                                                                                    |                          |                                  | authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0048/G | This was an application for a group of variations. B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                                                                                                                                                                         | 08/09/2011               | n/a                              | longer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| WS/0115   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of Summary of Product Characteristics, Annex II, Labelling and Package Leaflet following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of the Product information (PI) in line with the SmPC Guideline, revision 2, September 2009 and the current QRD template version 7.3.1. The MAH took this opportunity to harmonize the PI across the products Viread, Emtriva, Truvada and Atripla. Following CHMP request, section 4.6 \"fertility, pregnancy and lactation\" of the SmPC was updated product | 23/06/2011 19/08/2011 no | SmPC, Annex II, Labelling and PL | The MAH took this opportunity to harmonize the PI across the products Viread (tenofovir disoproxil fumarate), Emtriva (emtricitabine), Truvada (emtricitabine and tenofovir disoproxil fumarate) and Atripla (efavirenz, emtricitabine and tenofovir disoproxil fumarate). Following CHMP request section 4.6 of the SmPC on fertility, pregnancy and lactation was revised. A moderate amount of data mainly from the Antiretroviral Pregnancy Registry on pregnant women (between 300-1000 pregnancy outcomes) indicate no malformations or foetal / neonatal toxicity associated with tenofovir disoproxil fumarate nor with emtricitabine. |

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0044 | Update of the section 4.8 of the SmPC according to the SmPC Guideline (September 2009) Rev. 2 following CHMP request from the procedure II/29. The MAH took the opportunity of this variation to further update sections 4.2, 4.3, 4.4, 4.5 and 5.2 based on the SmPC Guideline and to align with the Product Information from the individual products including information related to hepatic failure. PL was update accordingly. Annex II was revised with editorial changes. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- | 18/11/2010 | 20/12/2010    | SmPC, Annex II and PL Update of the section 4.8 of the SmPC according to the SmPC Guideline (September 2009) Rev. 2 following CHMP request both as regards structure as well as regards the estimation of frequency for each adverse drug reaction to be in line with the SmPC of the individual products. The MAH took the opportunity of this variation to further update sections 4.2, 4.3, 4.4, 4.5 and 5.2 based on the SmPC Guideline and to align with the Product Information from the individual products including information related to hepatic failure. longer authorised |
| WS/0048 | clinical, clinical or pharmacovigilance data This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS product                                                                                                                                                                                                                                                                        | 21/10/2010 | 21/10/2010 no |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| WS/0047 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                    | 21/10/2010 | 21/10/2010    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                       |                    |               |                                  | authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|---------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0029 | Update of sections 4.2, 4.4, 4.5, 4.6 and 4.8 of the SmPC to align the information with the efavirenz product information and to include tenofovir related safety information in accordance with the Company Core Data Sheet (CCDS) version 3 for Atripla. The PL was updated in accordance. In addition, the MAH took this opportunity to update contact details of local representatives in the PL. Update of Summary of Product Characteristics and Package Leaflet | 18/03/2010 product | 10/05/2010 no | SmPC and PL                      | The Product Information of Atripla was updated to reflect recent updates of the efavirenz interaction information, as well as any available new information on interactions with emtricitabine and tenofovir DF. Aiming at the harmonisation of the wording with the efavirenz product information the dose adjustment to 800 mg/day (i.e. additional 200 mg/day) of efavirenz when Atripla is co- administered with rifampicin has been amended to reflect that this dose adjustment may be considered rather than recommended. Also, a statement was included in section 4.4 of the Atripla SmPC on closer monitoring of renal function in patients who have previously experienced renal events while receiving adefovir dipivoxil, similar to that already included in the Viread (tenofovir DF) and Truvada (emtricitabine/tenofovir DF) SmPCs. During the review of cases of possible allergic reaction, a total of 14 reports that involved angioedema or possible symptoms of angioedema were identified in which there was some evidence of a potential causal association with tenofovir DF- or emtricitabine-containing products. As a causal relationship could not be excluded, this adverse side effect was added to the Atripla SmPC as well. longer |
| IB/0041 | C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH Medicinal                                                                                                                                                                                                   | 16/04/2010         | n/a           | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IB/0042   | To change in-process controls during the manufacture of the finished product. B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                  | 12/04/2010         | n/a authorised          |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|-------------------------|
| IA/0040   | To introduce minor changes to the manufacturing parameters of the finished product. B.II.b.3.a - Change in the manufacturing process of the finished product - Minor change in the manufacturing process of an immediate release solid oral dosage form or oral solutions | 23/02/2010         | n/a longer              |
| IB/0039   | IB_07_c_Replacement/add. of manufacturing site: All other manufacturing operations ex. batch release                                                                                                                                                                      | 14/01/2010         | n/a no                  |
| IA/0038   | IA_01_Change in the name and/or address of the marketing authorisation holder                                                                                                                                                                                             | 28/08/2009 product | n/a SmPC, Labelling and |
| IB/0034   | IB_10_Minor change in the manufacturing process of the active substance                                                                                                                                                                                                   | 18/08/2009         | n/a                     |
| IA/0037   | IA_09_Deletion of manufacturing site                                                                                                                                                                                                                                      | 12/08/2009         | n/a                     |
| IA/0036   | IA_09_Deletion of manufacturing site Medicinal                                                                                                                                                                                                                            | 12/08/2009         | n/a                     |
| IA/0035   | IA_09_Deletion of manufacturing site                                                                                                                                                                                                                                      | 09/06/2009         | n/a                     |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IA/0032   | IA_07_b_01_Replacement/add. of manufacturing site: Primary packaging site - Solid forms                                                                                                                                                                                                                                          | 28/05/2009   | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0033   | IA_05_Change in the name and/or address of a manufacturer of the finished product                                                                                                                                                                                                                                                | 27/05/2009   | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IB/0031   | IB_14_b_Change in manuf. of active substance without Ph. Eur. certificate - new manufacturer                                                                                                                                                                                                                                     | 23/04/2009   | n/a        | authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IA/0030   | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site IA_07_b_01_Replacement/add. of manufacturing site: Primary packaging site - Solid forms                                                                                                                                                                 | 27/03/2009   | n/a        | longer                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IB/0027   | IB_17_b_Change in the storage conditions for the active substance                                                                                                                                                                                                                                                                | 25/03/2009   | n/a no     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IB/0026   | IB_42_a_01_Change in shelf-life of finished product - as packaged for sale                                                                                                                                                                                                                                                       | 25/03/2009   | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IA/0028   | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site                                                                                                                                                                                                                                                         | 17/03/2009   | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0019   | Update sections 4.1, 4.4, 4.8, 5.1 and 5.2 of the SPC to reflect the 48 week data results for study AI266073 comparing the efficacy and safety of the single regimen of Atripla with an unmodified HAART regimen in HIV-1 infected virologic suppressed patients. Update of Summary of Product Characteristics Medicinal product | 20/11/2008   | 22/12/2008 | The 48 week data from study AI266073, an open label study comparing the single tablet regimen Atripla to unmodified HAART in HIV 1 infected subjects who have achieved stable virologic suppression (< 200 copies/ml on two consecutive measurements for at least 3 months) on their current HAART regimen, confirmed the non inferiority of Atripla. However, the relevance of a conclusion on the overall population is somewhat disputable and confidence is |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IB/0023   | IB_33_Minor change in the manufacture of the finished product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 10/09/2008   | n/a           | hypokalaemia, hepatic steatosis, rhabdomyolysis, and muscular weakness as adverse reactions to Atripla treatment. It is also explained that rhabdomyolysis, osteomalacia, hypokalaemia, muscular weakness, myopathy, and hypophosphatemia may occur as a consequence of proximal renal tubulopathy associated with tenofovir DF treatment. authorised                                                                                                                                                                                                                                                                                                                                     |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0021   | IB_07_c_Replacement/add. of manufacturing site: All other manufacturing operations ex. batch release                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 10/09/2008   | n/a longer    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| II/0018   | Change(s) to the manufacturing process for the active substance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 26/06/2008   | 16/07/2008 no |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IA/0022   | IA_32_a_Change in batch size of the finished product - up to 10-fold                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 09/07/2008   | n/a           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| II/0008   | Update of section 4.5 of the SPC and section 2 of the PL with interaction with tacrolimus (study GS-US- 174-0105) and of sections 4.8 and 5.1 of the SPC with HIV-1 patients co-infected with HBV or HCV and resistance data from the 144 week analysis of study GS-01-934. These amendments align the Product Information for Atripla with its individual components, as agreed at the time of the initial Marketing Authorisation. In addition, minor linguistic changes were made in some of the EU version languages of the Annexes. 24/04/2008 Medicinal product | 18/06/2008   | SmPC and PL   | The lack of interaction observed between tacrolimus and the fixed-dose combination emtricitabine/tenofovir DF and the decreased exposure of tacrolimus levels expected when in co-administration with efavirenz are now reflected in the SPC of Atripla. Tacrolimus doses may require adjustment. Tacrolimus levels should be closely monitored at least two weeks of starting or stopping treatment with Atripla. The PL has been updated accordingly. The 144 week resistance analysis of study GS-01-934 (a randomised, open-label, parallel, active-controlled study designed to assess non-inferiority of tenofovir DF + emtricitabine + efavirenz relative to lamivudine/zidovudine |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

|         | Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                                                                                         |            |               | longer                 | + efavirenz in the treatment of HIV-1 infected antiretroviral nave patients) showed that mutations associated with resistance to efavirenz (predominantly K103N) or with resistance to emtricitabine or lamivudine (M184V/I) occurred less often in the emtricitabine + tenofovir DF group than in the lamivudine/zidovudine group. No subject developed the K65R mutation that can be selected by tenofovir. The SPC information on co-infected HIV-1/HBV (n=13) and HIV-1/HCV (n=26) patients included in study GS-01-934 was updated with data from the 144 week analysis. authorised   |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0003 | Update of the Detailed Description of the Pharmacovigilance System (DDPS) and the EU Risk Management Plan (RMP) to reflect the MAH change of name. The DDPS format is also updated in line with Volume 9 of the Notice to Applicants. Update of DDPS (Pharmacovigilance) | 24/04/2008 | 18/06/2008 no | Annex II               | The pharmacovigilance system and the EU risk management plan agreed at the time of the initial Marketing Authorisation for Atripla have been updated to reflect the MAH change of the name. Furthermore, the detailed description of the pharmacovigilance system has been updated to the format required by Volume 9 of the Notice to Applicants.                                                                                                                                                                                                                                          |
| IB/0020 | IB_41_a_02_Change in pack size - change in no. of units outside range of appr. pack size product                                                                                                                                                                         | 23/05/2008 | 23/05/2008    | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| IA/0017 | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.)                                                                                                                                                                       | 10/04/2008 | n/a           |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| IA/0016 | IA_09_Deletion of manufacturing site                                                                                                                                                                                                                                     | 10/04/2008 | n/a           |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| IA/0015 | IA_09_Deletion of manufacturing site Medicinal                                                                                                                                                                                                                           | 10/04/2008 | n/a           |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| IA/0014 | IA_04_Change in name and/or address of a manuf.                                                                                                                                                                                                                          | 10/04/2008 | n/a           |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | of the active substance (no Ph. Eur. cert. avail.)                                                                                                 |                        |                               |               |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|-------------------------------|---------------|
| IA/0013 | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site IA_07_b_01_Replacement/add. of manufacturing packaging site - Solid forms | 10/04/2008             | n/a authorised                | site: Primary |
| IA/0012 | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.)                                                 | 10/04/2008             | n/a                           |               |
| IA/0011 | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.)                                                 | 10/04/2008             | n/a                           |               |
| IA/0010 | IA_09_Deletion of manufacturing site                                                                                                               | 10/04/2008             | n/a longer                    |               |
| IA/0009 | IA_05_Change in the name and/or address of a manufacturer of the finished product                                                                  | 10/04/2008             | n/a no                        |               |
| N/0002  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                   | 14/02/2008 the product | n/a PL PL SmPC, Labelling and |               |
| IA/0004 | IA_09_Deletion of manufacturing site                                                                                                               | 14/02/2008             | n/a Annex II and              |               |
| IA/0001 | IA_01_Change in the name and/or address of marketing authorisation holder Medicinal                                                                | 14/02/2008             | n/a PL                        |               |
| IA/0007 | IA_09_Deletion of manufacturing site                                                                                                               | 08/02/2008             | n/a                           |               |
| IA/0006 | IA_09_Deletion of manufacturing site                                                                                                               | 08/02/2008             | n/a                           |               |

<div style=\"page-break-after: always\"></div>

<!-- image -->